Stock Ratings / Health Care / RLMD / earnings

SPRY (20) EBS (52) CYPH (45) GALT (39) ⌘ Pro Terminal →

Relmada Therapeutics Inc. (RLMD) Next Earnings Date & Expected ±12.5% Move

$3.58 +4.07% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.60

Relmada Therapeutics Inc. (RLMD) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $366.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RLMD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RLMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Relmada Therapeutics Inc. (NASDAQ: RLMD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $3.58 (+4.07% 1D, market cap $366.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RLMD compare to SPRY and EBS in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RLMD carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SPRY (ARS Pharmaceuticals Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $364.0M) and EBS (Emergent BioSolutions Inc.) posts a D+ grade (52/100 RQD, P/E 7.0x, ROIC 8.9%, cap $370.2M). Among the 5-stock peer group, EBS leads on earnings multiple (7.0x) while EBS leads on capital efficiency (8.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RLMD?

▼

Per RLMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001553643), Relmada Therapeutics Inc. generated $0 in revenue, $0 in net income, and -$45.8M in free cash flow against $94.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.60 (+0.54%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RLMD)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (30/100 Composite)

🔍 WHY RLMD SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Cash Engine Quality+6/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$3.51-10% Next Q

Q2 (-2Q)

Grade E$3.16+2.2% Next Q

Q3 (-1Q)

Grade E$3.23+10.8% Next Q

Current

Grade E$3.58-9.6% Hist 90D α

Trajectory: E (22) → E (30)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RLMD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RLMD currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.82) and Max Pain ($3.76) forces dealer call-delta covering toward $8.40.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RLMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RLMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 30%NO 70%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.45 Expected Swing

MODEL EARNINGS SETUP GAUGE

RLMD Quantitative Pre-Earnings Setup: 30/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (30/100)Model Risk Weight (70/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	$0	-$45.8M	52%
FY 2024	2024-12-31	$0	$0	-$51.8M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RLMD)

✓Walkthrough of RLMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RLMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -51.69%▲ RESISTANCE BREAKOUT

2026-11-02O $3.35H $3.58L $3.35C $3.58VOL 1.61M

RES: $3.33SUP: $2.58SMA50: $3.82SMA200: $5.36

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RLMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RLMD Butterfly Map → + Track RLMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RLMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RLMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RLMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RLMD)

Health Care Rank #846 of 1016 ⚔️ SPRY vs RLMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RLMD vs. SPRY, EBS, CYPH, GALT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Relmada Therapeutics Inc. (RLMD) ranks #846 by composite RQD confidence (30/100, grade E) and #494 by equity capitalization ($366.9M). Within this direct 5-issuer industry benchmark cohort, EBS leads on earnings valuation at 7.0x trailing P/E, while EBS leads on capital efficiency and profitability with 8.9% ROIC and 56.1% gross margin. EBS currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with RLMD at 30/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RLMD ACTIVE Relmada Therapeutics Inc.	E	30/100	—	—	-35.0%	+4.07%	$366.9M	Benchmark Subject
SPRY ARS Pharmaceuticals Inc.	E	20/100	—	—	-35.0%	-7.65%	$364.0M	/spry-vs-rlmd →
EBS Emergent BioSolutions Inc.	D+	52/100	7.0x	56.1%	8.9%	-5.68%	$370.2M	/ebs-vs-rlmd →
CYPH Cypherpunk Technologies Inc.	D	45/100	71.3x	—	-23.3%	-9.97%	$356.7M	/cyph-vs-rlmd →
GALT Galectin Therapeutics Inc.	D-	39/100	—	—	-35.0%	-5.68%	$355.8M	/galt-vs-rlmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001553643

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Relmada Therapeutics Inc. (RLMD) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $0, operating cash flow of -$45.8M, and free cash flow of -$45.8M (+11.5% YoY). On the balance sheet, RLMD closed FY2025 with $94.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	-$45.8M	-$45.8M	$94.0M	—
FY2024 (FY)	2024-12-31	$0	$0	-$51.8M	-$51.8M	$45.8M	—

3. RLMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RLMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does RLMD compare to SPRY and EBS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for RLMD?

Where is RLMD trading relative to its 50-day, 200-day, and 52-week technical levels?

RLMD last traded at $3.58 (+4.07% on volume of 1,413,760 shares), positioning the stock -6.28% below its 50-day simple moving average ($3.82) and -33.21% below its 200-day simple moving average ($5.36). Across its 52-week range of $2.15 to $8.00, RLMD sits at the 24.4% percentile with a 14-day RSI of 47.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.13 to $4.03).

RLMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is RLMD's next earnings date?

Based on SEC filing cadence, Relmada Therapeutics Inc. (RLMD)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is RLMD stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for RLMD, spanning a range between $3.13 and $4.03.

Direct Sub-Reports: RLMD RQD Cockpit RLMD 12M Forecast RLMD Earnings & Move RLMD Dividends & DRIP RLMD Insiders & 13F RLMD Whale Options RLMD Profit Sankey RLMD News & Why

ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

RLMD — Relmada Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:37:42Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, RLMD scores 30 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 6/20 (ROIC of -35%; FCF yield of -12.48%), Whale 13F Flow at 5/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 6/20 (Beta of 1.0; sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z of 2.5; Piotroski F of 1/9; Debt/Equity of 0.5). Taken together, the low scores on cash generation, insider conviction, and institutional flow mean the rating does not identify an upside driver strong enough to offset the negative free cash flow profile. For a prospective investor, the practical implication is that any upside thesis would have to rest on a future event outside the reported cash engine, such as a pipeline milestone, rather than on current earnings power. The Forensic Balance Sheet pillar, the strongest of the five at 10/20, still carries a low Piotroski F-Score of 1/9, which signals weak financial health indicators.

Business

Relmada Therapeutics Inc. is a NASDAQ-listed issuer classified in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company has a market capitalization of $0.4B. The source data does not describe its products, customers, or revenue model. Reported revenue is $0.0M for both FY 2025 and FY 2024 in the SEC financials, indicating no revenue recognition in the reported periods.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-59.1M	$0.0M	N/A	$-45.8M	$3.5M	N/A
FY 2024	$0.0M	$-83.9M	$0.0M	N/A	$-51.8M	$3.9M	N/A

Per the SEC financials, operating losses were $-59.1M in FY 2025 and $-83.9M in FY 2024, and free cash flow was negative in both periods. Per the market data, gross, operating, and net margins are each reported as 0%, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9, both per the Roarable RQD rating. Per the same rating, Debt/Equity is 0.5, while the debt line in the SEC financials is reported as N/A.

Recent Catalysts & News Wire Analysis

The news feed contains six items, all tagged to RLMD and all carrying a YELLOW light and "MARKET WIRE" impact label. The headlines reference a Seasonal Returns Chart, an options chain, a Q2 2026 earnings call transcript, a Q3'26 earnings preview listing a revenue estimate of 0 USD, a piece on Allarity Therapeutics (ALLR) described as a "buy the bottom" candidate, and a general U.S. stock listing. The summaries are generic and do not disclose trial results, regulatory actions, or deal terms. Per the Butterfly Supply-Chain Graph, a proprietary LIQUIDITY_TAILWIND signal with a severity score of 94 is marked BULLISH, with a macro tailwind score of 96/100 and a 4.19 z-score across FRED Fed Assets, US Treasury TGA, and ON RRP feeds. The same signal reports true net liquidity of $5,746B, a 4-week rate of change of -0.64%, and a 2 bps delta in high-yield OAS. It also cites a high 4.02x beta elasticity to net liquidity and an inverse Pearson correlation of -0.16. This signal is macro in nature and is not tied to a company-specific catalyst.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE and there are no butterfly links, so no upstream or downstream dependencies are mapped in the source data. The only cross-market linkage is the macro liquidity signal, which implies the stock's sensitivity to broad liquidity conditions rather than to any specific supplier or customer. Because the graph shows a high beta elasticity to net liquidity, a prospective investor should note that liquidity-driven moves could amplify price changes in either direction. The news feed's reference to Allarity Therapeutics (ALLR) is the only named peer, and the source data does not establish a supply-chain or competitive relationship between the two companies.

Open Questions

What are the company's products, pipeline stages, and clinical or regulatory milestones, given that the source data does not describe them?
Why is reported revenue $0.0M in both periods, and what is the expected timing of any revenue or partnership income?
What is the company's debt position, given that the SEC financials report debt as N/A while the RQD rating cites a Debt/Equity of 0.5?
What is the cash runway implied by $3.5M in cash against negative free cash flow of $-45.8M in FY 2025?
What would explain the 52-week price range of $2.15 to $8, and what drove the stock's recent 2.69% move?

RLMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Relmada Therapeutics Inc. (RLMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RLMD Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 14h ago

Relmada Therapeutics, Inc. (RLMD) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 17h ago

Relmada Therapeutics(RLMD) Stock Options Chain | Quotes & News

Moomoo report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 20h ago

Full Transcript: Relmada Therapeutics Q2 2026 Earnings Call

Benzinga report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 23h ago

RLMD Q3'26 Earnings: revenue estimate is 0 USD

TradingView report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Here's Why Allarity Therapeutics, Inc. (ALLR) Is a Great 'Buy the Bottom' Stock Now

Yahoo Finance report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Complete U.S. Stocks List: Prices, Performance and Key Data

TradingKey report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

Alpha Buying: 4 Biotech Stocks Insiders Are Betting On

Benzinga report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

TRex Bio (TRXB) Stock Price, News & Analysis

Stock Titan report covering Relmada Therapeutics Inc. (RLMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RLMD Bull vs. Bear Conversation Board — What's Your Call at $3.58?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RLMD 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $3.03 (-11.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is RLMD (E • RQD 30/100) a Buy at $3.44?

Welcome to the RLMD (Relmada Therapeutics Inc.) Roar Pit. Current RQD Composite is 30/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.68 (-22.1%)

Spot @ $3.44

Pump the brakes on RLMD — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on RLMD, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Relmada Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $3.96 (+15.1%)

Spot @ $3.44

RLMD cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on RLMD, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.44 (52-wk range $2.15 - $8.00), any beat on forward guidance forces shorts and underweight funds to chase.